(Reuters) - Biotechnology company InterMune Inc's quarterly revenue missed analysts' estimates as sales of its lung-scarring drug Esbriet fell short of expectations, sending the company's shares down as much as 14 percent. InterMune posted quarterly revenue of $5.5 million, all of which came from Esbriet, compared with analysts' expectations of revenue of $40 million, according to Thomson Reuters I/B/E/S. The company expects full-year revenue from Esbriet to be between $20 million and $25 million. Analysts on an average are expecting the company to post full-year revenue of $77.9 million. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment